SCHEMBL2003422

SCHEMBL2003422

[NH]C(=O)N1C=Nc2ccccc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NOTUM Q6P988 1/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
TRPA1 O75762 6/20 0.34
BCHE P06276 3/20 0.33
ACHE P22303 3/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
HSP90B1 P14625 1/20 0.33
TRAP1 Q12931 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
NAMPT P43490 1/20 0.33
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30525283 0.84 NPC1 (0.53) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL30525272 0.84 NPC1 (0.53) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL4049974 0.84 NPC1 (0.53) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL6053120 0.83 NPC1 (0.51) NPC1HPGDRAB9ASMN1; SMN2NOTUM
Hydrochloric Acid SCHEMBL6053028 0.83 NPC1 (0.56) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL2003424 0.83 NPC1 (0.47) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL4430006 0.83 NPC1 (0.47) NPC1HPGDRAB9ASMN1; SMN2NOTUM
SCHEMBL28183068 0.83 NPC1 (0.51) NPC1HPGDRAB9ASMN1; SMN2NOTUM
Potassium Ion SCHEMBL6053118 0.81 NPC1 (0.46) NPC1HPGDRAB9ASMN1; SMN2NOTUM
Hydrochloric Acid SCHEMBL20640295 0.81 NPC1 (0.50) NPC1HPGDRAB9ASMN1; SMN2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 NPC1 1762/4885HPGD 1054/4885RAB9A 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.